American Society of Hematology (ASH) Meeting

Coverage

PET Can Identify Low-Risk Patients With Hodgkin's Lymphoma Who Need No Further Treatment Following Three Cycles of ABVD
   |    ASH_2012 > Henri Stanton
At the 54th Annual Meeting of the American Society of Hematology, John Radford, MD, reported the results of the United Kingdom RAPID trial, in which PET-directed therapy provided an opportunity to avoid involved field radiotherapy, the current standard of care following abbreviated chemotherapy in early stage Hodgkin's lymphoma.
   |    ASH_2012
Ralph M. Meyer, MD, Director of Clinical Trials Group, National Cancer Institute of Canada, Queen's University, offers a counterpoint to the thoughts of Richard T. Hoppe, MD, on the role and utility of radiation therapy in patients with early stage Hodgkin's lymphoma.
   |    ASH_2012 > Bonnie Gillis
Vorinostat added to standard chemotherapy before, during, and after hematopoietic stem cell transplantation reduced the cumulative incidence of graft-versus-host disease in a phase I/II trial reported at the 54th Annual Meeting of the American Society of Hematology.
   |    ASH_2012
Adrian Wiestner, MD, PhD, Investigator, Laboratory of Lymphoid Malignancies, National Heart Lung and Blood Institute, discusses the patient outcomes that clinical trials have demonstrated regarding the use of targeted kinase inhibitors for the management of chronic lymphocytic leukemia (CLL).
   |    ASH_2012 > Henri Stanton
A unique targeted therapy, quizartinib, was able to clear leukemia cells from the bone marrow in more than 33% of patients with an aggressive form of acute myeloid leukemia marked by a mutation in the FLT3 gene.
   |    ASH_2012
Elisabeth M. Paietta, PhD, Professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, defines minimum residual disease (MRD) and discusses its clinical significance. She then describes the methodological and therapeutic challenges that face clinical MRD implementation.
   |    ASH_2012 > Bonnie Gillis
An investigational, weekly, oral proteosome inhibitor called MLN9708 achieved excellent response rates when combined with lenalidomide and dexamethasone as up-front treatment of newly diagnosed patients with multiple myeloma, according to results of a phase II trial presented at the 54th Annual Meeting of the American Society of Hematology.
   |    ASH_2012
Thomas P. Loughran, Jr, MD, Professor of Medicine, Penn State University, Director, Penn State Hershey Cancer Institute, describes the clinical sequelae of large granular lymphocyte (LGL) leukemia, particularly noting neutropenia and anemia, and discusses the pharmacotherapeutic approach.
Feature
$vacMongoViewPlus$